IKhomishini yaseYurophu yazisa ukuhlaziywa kwiSihlomelo XVII soMgaqo we-REACH kunye nezithintelo ezintsha kwi-N, N-dimethylacetamide (DMAC) kunye ne-N-ethylpyrrolidone (NEP). Ingenise iSaziso G/TBT/N/EU/1079 kwi-WTO ngoJulayi 30, 2024. Olu tshintsho lumiselwe ukusebenza kwiintsuku ezingama-20 emva kokupapashwa kwi-EU Official Journal.
Isihlomelo XVII sithintela ukusetyenziswa kweekhemikhali ezithile eziyingozi kwimarike ye-EU. Ukufakwa kwe-DMAC kunye ne-NEP kuya kubeka ezi khemikhali kulawulo olungqongqo, ukuqinisekisa ukuba zonke iimveliso eziziphetheyo, nokuba ziveliswe okanye zithengiswa kwi-EU, ziyahlangabezana nemigangatho engqongqo yokhuseleko lokukhusela impilo kunye nokusingqongileyo.
Uhlaziyo oluthile lulandelayo.
| Igama leziyobisi | Inombolo yeCAS./Hayi. | Umlinganiselo wothintelo |
| I-Dimethylacetamide (DMAC) | 127-19-5204-826-4 | Ayiyi kufakwa kwimarike njengento yodwa, njengenxalenye yezinye izinto, okanye kwimixube ekugxininiseni elilingana okanye elingaphezulu kwe-0.3 % emva komhla [umhla] ngaphandle kokuba abavelisi, abangenisa kumazwe angaphandle kunye nabasebenzisi abasezantsi babandakanyiwe kwiingxelo zokhuseleko lweekhemikhali kunye nokhuseleko lwamaphepha edatha yokhuseleko, Amanqanaba aphuma kwi-No-Effect (DNELs) enxulumene nokuvezwa kwe-13 mg kunye nexesha elide labasebenzi. I-3 mg / kg / ngosuku kwi-dermal exposure yexesha elide.Ayiyikwenziwa, okanye isetyenziswe, njengento yodwa, njengenxalenye yezinye izinto, okanye kwimixube ekugxininiseni okulinganayo okanye ngaphezulu kwe-0.53 % emva kokuba [umhla njengoko kumhlathi 0.3] ngaphandle kokuba abavelisi kunye nabasebenzisi abasezantsi bathatha amanyathelo afanelekileyo okulawula umngcipheko kwaye bathathe amanyathelo afanelekileyo okulawula ingozi kunye nokuqinisekisa ukuba i-exposure yabasebenzi i-exposure echazwe ngezantsi kwe-DNEL kumhlathi ochanekileyo. 1. |
| I-1-ethyl-2-pyrrolidinon (NEP) | 2687-91-4220-250-6 | Akuyi kufakwa kwimarike njengento yodwa, njengenxalenye yezinye izinto, okanye kwimixube ekugxininiseni okulinganayo okanye ngaphezulu kwe-0.3 % emva komhla [umhla] ngaphandle kokuba abavelisi, abathumeli kunye nabasebenzisi abasezantsi baye bafaka kwiingxelo zokhuseleko lweekhemikhali kunye namaphepha edatha yokhuseleko, I-Derived No-Effect Levels (DNELs) enxulumene nokuvezwa kwe-4.0 mg / 3 ixesha elide labasebenzi. Utyhileko olubukhali ngokuphefumla kunye ne-4.6 mg/kg/ngosuku lokuvezwa kwesikhumba ixesha elide.Ayiyi kuveliswa, okanye isetyenziswe, njengento yodwa, njengenxalenye yezinye izinto, okanye kwimixube ekugxininiseni okulinganayo okanye ngaphezulu kwe-2.4 % emva kokuba [umhla njengoko kumhlathi 0.3] ngaphandle kokuba abavelisi kunye neemeko ezifanelekileyo zokulawula umngcipheko wabasebenzi bathatha amanyathelo afanelekileyo okulawula umngcipheko wabasebenzi kwaye bathathe amanyathelo afanelekileyo okulawula umngcipheko wabasebenzi abaphantsi komlambo kunye nokuqinisekisa ukuba abasebenzi kunye neemeko ezifanelekileyo zokulawula umngcipheko wabasebenzi bathatha amanyathelo afanelekileyo okulawula umngcipheko wabasebenzi. zombini ii-DNEL ezichazwe kumhlathi woku-1. |
Ukuba ufuna naluphi na uncedo okanye unemibuzo, nceda uqhagamshelane nathi nge service@cirs-group.com.
Umthombo ovela CIRS
Ukuziphendulela: Ulwazi olubekwe ngasentla lunikezelwa yi-cirs-group.com ngokuzimeleyo kwe-Cooig.com. I-Cooig.com ayenzi lumelo kunye neziqinisekiso malunga nomgangatho kunye nokuthembeka komthengisi kunye neemveliso. I-Cooig.com ikhupha ngokucacileyo naliphi na ityala lokwaphulwa kwelungelo lokushicilela umxholo.
